FDA Approves RSV Vaccine for Pregnant Women to Help Protect Newborns
Abrysvo indicated to be given between 32 and 36 weeks of pregnancy to prevent lower respiratory tract disease caused by RSV in infants from birth through 6 months
Breastfeeding for at Least Six Months Aids Maternal Cardiovascular Factors
Findings similar for women who experienced a complication of pregnancy
WHO Monitoring Highly Mutated New Strain of COVID-19, Now Spotted in Michigan
Four known cases of the variant, dubbed BA.2.86, have so far been identified worldwide, including the case in Michigan
Better Responses Seen With Booster mRNA COVID-19 Vaccine in Pregnancy
Robust immune responses found after booster dose; efficient transplacental antibody transfer was seen
Oral Piroxicam Plus Levonorgestrel Increases Efficacy of Emergency Contraception
Levonorgestrel plus piroxicam prevented 94.7 percent of expected pregnancies compared with 63.4 percent with levonorgestrel plus placebo
Pediatricians’ Group Urges That All Infants Get New RSV Shot
The American Academy of Pediatrics recommendation applies to infants 19 months of age or younger
U.S. COVID-19 Hospitalizations Rise for Fourth Straight Week
The variant EG.5 is now the dominant variant in the country, comprising 17.3 percent of U.S. infections
Most Infants With RSV-Related Critical Illness Born at Term
Risk for intubation higher for infants younger than 3 months, those born prematurely, publicly insured
Exercise Intervention Beneficial for Health Care Workers
12-week app-based intervention reduced depressive symptoms, burnout, and absenteeism
New COVID-19 Variant EG.5 Now Dominant in U.S., CDC Says
EG.5 is one of several closely related omicron subvariants that have been competing for dominance in recent months
